Fate Therapeutics Q1 2025 Update
Ticker: FATE · Form: 10-Q · Filed: May 13, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, collaboration
TL;DR
Fate Therapeutics Q1 2025: Financials filed, showing investments and partnerships with Ono Pharma & MSKCC.
AI Summary
Fate Therapeutics Inc. reported its first quarter results for the period ending March 31, 2025. The company's financial statements indicate various assets and liabilities, including investments in U.S. Treasury Securities and other long-term investments. Specific details on revenue, net income, or cash flow are not provided in this excerpt, but the filing references agreements with entities like Ono Pharmaceutical Company Ltd. and Memorial Sloan Kettering Cancer Center (MSKCC).
Why It Matters
This filing provides a snapshot of Fate Therapeutics' financial position and ongoing collaborations as of Q1 2025, which is crucial for investors assessing the company's operational status and potential future developments.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the biotech sector inherently carries high risk due to R&D uncertainties and regulatory hurdles.
Key Numbers
- N/A — Revenue (Specific revenue figures not detailed in this excerpt.)
- N/A — Net Income (Specific net income figures not detailed in this excerpt.)
- N/A — Cash Flow (Specific cash flow figures not detailed in this excerpt.)
Key Players & Entities
- FATE THERAPEUTICS INC (company) — Filer
- Ono Pharmaceutical Company Ltd (company) — Collaboration partner
- Memorial Sloan Kettering Cancer Center (company) — Licensing partner (AmendedMskccLicenseMember)
- 2025-03-31 (date) — End of reporting period
- 2025-01-01 (date) — Start of reporting period
FAQ
What was the specific financial performance of Fate Therapeutics in Q1 2025?
This excerpt does not provide specific figures for revenue, net income, or cash flow for the three months ended March 31, 2025.
What are the key assets mentioned in the filing for the period ending March 31, 2025?
The filing mentions assets such as U.S. Treasury Securities, Other Current Assets, and Other Long-Term Investments as of March 31, 2025.
Does the filing detail any new collaborations or updates to existing ones?
The filing references agreements with Ono Pharmaceutical Company Ltd. and an Amended MSKCC License, indicating ongoing or updated collaborations.
What is the fiscal year-end for Fate Therapeutics?
Fate Therapeutics Inc.'s fiscal year ends on December 31.
What is the SIC code for Fate Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Fate Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding FATE THERAPEUTICS INC (FATE).